The present disclosure provides systems, methods, and compositions for delivering endothelial cells into Schlemm's canal to restore physiological outflow in glaucoma and other ocular disorders. The document encompasses diverse devices and hydrogel carriers suitable for delivering endothelial cells, including conduits, microcatheters, scaffolds, stents, support devices, Schlemm's canal expanders, viscodilation balloons, tensioning sutures, hydrogel sleeves, and injectable formulations. The endothelial cells may be combined with extracellular matrix components, drugs, or growth factors, and may be delivered using controlled-release hydrogels to ensure uniform circumferential seeding. The system enables removal of dysfunctional Schlemm's canal endothelial cells, OCT/OCTA-guided functional analysis, and re-endothelialization via bioengineered scaffolds. Embodiments further integrate artificial intelligence for intraoperative guidance, predictive analytics, and postoperative monitoring of endothelial integration. Safe dosing strategies are disclosed to avoid canal obstruction, and commercial applications include combination biologic-device products and digital health solutions.

Circulating cell clusters found in subjects with cancer, autoimmune conditions, infections, or other diseases, can be trapped or disrupted by filtering them with an intra- or extracorporeal device and, in some cases, exposing them to a substance, such as enzyme, that reduces intercellular adhesion.

A peristaltic pump-based apparatus for capturing circulating tumor cells (CTCs) from blood is provided that includes a feedback control architecture that uses models of pump operation and measures of internal pressure fluctuations of the pump (e.g., in the form time-varying and/or position-dependent pressure oscillation data) to adjust pump operating characteristics that smooth pump operation, thereby improving viscosity and consistency of fluid flowing through the pump to a connected microfluidic capture device.